

High-Sensitivity SARS-CoV-2 Nucleoprotein Antibody Pair For Rapid COVID-19 Antigen Assays

In May 2020, the FDA announced the approval of the first antigen test to help in the rapid detection of the virus that causes COVID-19.

Molecular tests are typically more sensitive and can diagnose an infection early in the process, but they must be carried out by trained technicians in a laboratory and they take time to report a result.

Rapid antigen tests can provide a result in minutes and can be produced at a lower cost in large scales. Antigen tests are very specific for the virus but not as sensitive as PCR. A positive result by an antigen test is highly accurate, but a negative result does not rule out an infection.

The performance of a rapid antigen test is limited by the sensitivity of the antibodies used. Meridian's new pair of monoclonal antibodies are highly sensitive for the detection of SARS-CoV-2 Nucleoprotein and they do not cross-react with seasonal coronavirus strains. They are ideal for developing reliable and sensitive rapid lateral flow antigen assays for the detection of active COVID-19 infections.

SARS-CoV-2 Nucleoprotein Antibody Pair

- ✓ >95% purity (Protein G)
- ✓ Validated for Lateral Flow & ELISA
- ✓ This antibody pair does not cross-react with other coronaviruses, except SARS (2003).

Capture Antibody:

Cat# 9548 MAb to SARS-CoV-2 NP

Detection Antibody:

Cat# 9547 MAb to SARS-CoV-2 NP

Ordering information:

USA
5171 Wilfong Road
Memphis, Tennessee 38134
Fax: +1 901-333-8223
Toll Free: +1 800 327 6299

Email: info@meridianlifescience.com
Orders: orders@meridianlifescience.com
www.MeridianLifeScience.com

meridian BIOSCIENCE™
LIFE DISCOVERED. LIFE DIAGNOSED.

Connect with us:

